

**A six-year prospective study of the prognosis and predictors in patients with late-life depression.**

Hans W. Jeurings<sup>1,2</sup>, M.D.; Max L. Stek<sup>1,2</sup>, M.D., Ph.D.; Martijn Huisman<sup>2</sup>, Ph.D.; Richard C. Oude Voshaar<sup>3</sup>, M.D., Ph.D.; Paul Naarding<sup>4</sup>, M.D., Ph.D.; Rose M. Collard<sup>5</sup>, Ph.D.; Roos C. van der Mast<sup>6</sup>, M.D., Ph.D.; Rob M. Kok<sup>7</sup>, M.D., Ph.D.; Aartjan T.F. Beekman<sup>1,2</sup>, M.D., Ph.D.; Hannie C. Comijs<sup>1,2</sup>, Ph.D.

<sup>1</sup> Department of Psychiatry, GGZ inGeest - VU University Medical Center, Amsterdam, the Netherlands.

<sup>2</sup> Department of Epidemiology and Biostatistics and the Amsterdam Public Health research institute, VU University Medical Center, Amsterdam, the Netherlands.

<sup>3</sup> University Center for Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.

<sup>4</sup> GGNet, Department of Old Age Psychiatry, Apeldoorn, the Netherlands.

<sup>5</sup> Radboud university medical center, Department of Psychiatry, Nijmegen, the Netherlands.

<sup>6</sup> Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands. Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium.

<sup>7</sup> Parnassia Psychiatric Institute, The Hague, the Netherlands.

**Corresponding author:** H.W. Jeurings, M.D., VU University Medical Center, LASA

Postal Box 7057, 1007 MB Amsterdam, the Netherlands.

Phone +31 20 444 6770, Fax: +31 20 444 6775, E-Mail: [h.jeurings@vumc.nl](mailto:h.jeurings@vumc.nl)

**Authorship:** All authors have reviewed and approved the manuscript prior to its submission.

**Disclosures:** No Disclosures to Report.

**Abstract** (Words: 234/250)

**Objectives:** To examine the six-year prognosis of patients with late-life depression and to identify prognostic factors of an unfavorable course.

**Design and setting:** The Netherlands Study of Depression in Older persons (NESDO) is a multi-site naturalistic prospective cohort study with six-year follow-up.

**Participants:** 378 clinically depressed patients according to DSM-IV-TR criteria and 132 non-depressed comparisons were included at baseline between 2007-2010.

**Measurements:** Depression was measured by the Inventory of Depressive Symptoms at six-month intervals and a diagnostic interview at two-year and six-year follow-up. Multinomial regression and mixed model analyses were both used to identify depression-related clinical, health and psychosocial prognostic factors of an unfavorable course.

**Results:** Among depressed patients at baseline, 46.8% were loss to follow-up, 15.9% had an unfavorable course, i.e. chronic or recurrent, 24.6% had partial remission, and 12.7% had full remission, at six-year follow-up. The relative risk (RR) of mortality in depressed patients was 2.5 (95%-CI:1.26-4.81) when compared with non-depressed comparisons. An unfavorable course of depression was associated with a younger age of depression onset, higher symptom severity of depression, pain, neuroticism, and loneliness at baseline. Additionally, partial remission was associated with chronic diseases, and loneliness at baseline when compared with full remission.

**Conclusions:** The long-term prognosis of late-life depression is poor with regard to mortality and course of depression. Chronic diseases, loneliness, and pain may be used as putative targets for optimizing prevention and treatment strategies of relapse and chronicity.

**Key words:** Depression; Old Age; Risk Factors; Prognosis; Outcome.

## **Introduction (Words: 558)**

Late-life depression is a complex and heterogeneous disorder, often accompanied by an unfavorable prognosis.<sup>1</sup> It has been associated with a chronic course,<sup>2</sup> a higher risk of subsequent development of cognitive impairment or dementia,<sup>3</sup> and premature death.<sup>4</sup> Although late-life depression can be treated effectively, relapse and recurrence as well as chronicity are a major problem in daily practice. Studies on the long-term prognosis of late-life depression are required to inform clinicians and to identify prognostic factors that may contribute to the improvement of treatment strategies and relapse prevention.

An unfavorable prognosis of late-life depression has been demonstrated in both community samples,<sup>5-8</sup> and clinical samples.<sup>9-14</sup> Beekman et al. (2002) studied the six-year course of community-dwelling older adults with late-life depression, using both diagnostic interviews and self-reports, and found that 32% had a severe chronic course and 44% an unfavorable but fluctuating course, whereas only 23% showed remission.<sup>6</sup> In our previous two-year follow-up study of the Netherlands Study of Depression in Older persons (NESDO), we found that nearly 50% of the clinically depressed patients still had a depression diagnosis, and 61% had a chronic course of depressive symptoms.<sup>13</sup> It is known that depression in older adults is more likely to have a chronic or chronic-relapsing course compared to younger adults.<sup>2,15</sup> Since meta-analyses of treatment studies have demonstrated equal efficacy of antidepressants among all ages,<sup>16</sup> suboptimal maintenance treatment may be an explanation for the less favorable prognosis in older adults. Also, some specific depressive syndromes occur more often in later life, such as the depression-executive dysfunction syndrome with apathy,<sup>17</sup> which has particularly been linked to a poor outcome.<sup>18,19</sup>

Currently, there has been an increasing interest to identify distinct long-term trajectories of depressive symptoms using latent class analyses. Hybels et al. (2016) identified four trajectory classes in a clinical sample of depressed older adults after three-years of follow-up, including a quick recovery class (43%), a persistent moderate symptom class (27%), a persistent high symptom class (15%), and a slow recovery class (15%).<sup>12</sup> Higher perceived stress and lower social support were associated with the persistent high symptom class.<sup>12</sup> These trajectories have proved to be useful in obtaining a better insight in the course of late-life depression, for example, by distinguishing a fast recovery class from a slow recovery class.<sup>12,20</sup> However, its use for clinicians may be limited, for they rely on a depression diagnosis for the management of depression, not on depressive symptoms only.

Multiple factors from different domains of functioning contribute to the onset and prognosis of depression.<sup>21</sup> For clinical purpose, prognostic factors may be assigned to a depression-related clinical domain, a health and lifestyle domain, and a psychosocial domain. Several factors from these domains have been associated with an unfavorable course of depression, including comorbid anxiety,<sup>22</sup> sleep problems,<sup>23</sup> chronic diseases,<sup>13,15</sup> functional limitations,<sup>24</sup> pain,<sup>25</sup> loneliness,<sup>26</sup> lack of social support,<sup>12</sup> childhood trauma,<sup>27</sup> and neuroticism.<sup>28</sup> Whether these factors are also associated with the prognosis of depression on the long-term remains to be explored.

The aim of the present study was twofold. First, the long-term prognosis of late-life depression was examined, in terms of both main reasons for attrition and course types, in clinically depressed patients over six-years. Second, prognostic factors of long-term course types were identified. We hypothesized that the long-term prognosis of late-life depression is poor, with a high mortality rate and an unfavorable course, including recurrence and chronicity, in most patients.

## **Methods (Words: 1284)**

### Study Design

The Netherlands Study of Depression in Older persons (NESDO) is a multi-site prospective cohort study designed to examine the course and consequences of depressive disorders in older adults ( $\geq 60$  years). Sampling procedures have been previously described in detail.<sup>29</sup> In short, data collection of the baseline measurement took place between 2007 and 2010.

Depressed patients were recruited in five regions in the Netherlands from both mental health care facilities and general practitioners. Non-depressed comparisons were recruited from general practitioners and were included if they had no lifetime diagnosis of depression. Participants were excluded when they had a dementia diagnosis, or were suspected for dementia based on clinician's judgment. Follow-up assessments by means of a face-to-face interview were performed two-years,<sup>13</sup> and six-years after baseline using the same measurement instruments as at baseline. Additionally, postal assessments were performed every six-months, including a questionnaire on self-reported depressive symptoms. Well-trained research assistants conducted the interviews. All interviews were audio taped and quality controlled. The research coordinator regularly evaluated interviews on the basis of their audiotapes. Question wording and probing behavior of interviewers were regularly monitored by checking a random selection of each interviewer. Written informed consent was obtained from all participants. NESDO' study protocol has been approved centrally by the Ethical Review Board of the VU University Medical Center, and subsequently by the ethical review boards of the Leiden University Medical Center, University Medical Center Groningen, and the Radboud university medical center Nijmegen.

## Sample

At baseline, NESDO included 378 depressed patients, having major depressive disorder (n=265), dysthymia (n=6), double depression (n=94) (major depression and dysthymia) or minor depression (n=13) according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR criteria),<sup>30</sup> and 132 non-depressed comparisons, aged  $\geq 60$  years.<sup>13</sup> Depressed patients did not differ from non-depressed comparisons with respect to mean age and sex, but depressed patients had less education, were more often divorced or widowed, and had lower cognitive functioning. From the 510 respondents at baseline, 401 were retained in the two-year follow-up assessment with an overall attrition rate of 21.4%.<sup>13</sup>

## Measurements

### Depression

The DSM-IV-TR-diagnosis of major depression, dysthymia and minor depression was assessed with the Composite Interview Diagnostic Instrument (CIDI, WHO, version 2.1) at two- and six-year of follow-up.<sup>30</sup> Severity of depressive symptoms was measured by a postal assessment every six months as a continuous variable with the Inventory of Depressive Symptoms (IDS),<sup>31</sup> which is a 30-item self-report scale that was developed to assess all core criterion diagnostic depressive symptoms. The IDS scores range between 0 and 84 with higher scores indicating more severe depression. An IDS score  $< 14$  was defined as no depression.<sup>32</sup> The scale has acceptable psychometric properties in depressed outpatients,<sup>31</sup> and depressed inpatients.<sup>32</sup> Cronbach's alpha for the IDS in our sample was 0.83.

## Course types

The course types were categorized according to the two-year and six-year measurement into: a) full remission, b) partial remission, c) recurrent, and d) chronic, using both the symptom severity level (according to the IDS) and diagnosis of depression (according to the DSM-IV-TR). Full remission was defined as the absence of a depression diagnosis at six-year follow-up, combined with an IDS score  $< 14$  at six-year follow-up (at measurement cycles 12 and 13, thereby covering six months). Partial remission was defined as the absence of a depression diagnosis at six-year follow-up, but with an IDS score  $\geq 14$  at six-year follow-up (at measurement cycle 12 and 13). Absence of a depression diagnosis at two-year, but presence of a diagnosis at six-year was labeled as 'recurrent'. Presence of a depression diagnosis both at two- and six-year follow-up was labeled as 'chronic'. The last two categories (recurrent and chronic) were based on diagnosis of depression according to the CIDI only.

## Prognostic factors

*Demographics* were assessed using standard questions and included sex, age, and educational level (years). The following *depression-related clinical factors* were included: previous episode of depression, age of onset of depression and comorbid anxiety diagnosis (y/n) were assessed by the CIDI, severity of depressive symptoms was assessed by the IDS,<sup>31</sup> severity of anxiety symptoms was assessed by the Beck Anxiety Index (BAI),<sup>33</sup> global cognitive functioning was assessed by the Mini Mental State Examination (MMSE),<sup>34</sup> apathy was assessed by the Apathy Scale (AS),<sup>35</sup> sleep problems was assessed by the Women's Health Initiative Insomnia Rating Scale (WHIIRS),<sup>36</sup> use of antidepressants and frequent use of benzodiazepines were assessed by inspection of the medication. The following health and

*lifestyle factors* were included: chronic physical diseases were self-reported and assessed by the LASA Questionnaire (LAPAQ),<sup>37</sup> functional limitations were assessed by the WHO-Disability Assessment Scale II (WHODAS 2.0),<sup>38</sup> metabolic syndrome was assessed by the original ATP-III criteria,<sup>39</sup> chronic pain was assessed by the Chronic Graded Pain Scale (CPGS),<sup>40</sup> body-mass-index was measured by weight (kg)/squared height (m<sup>2</sup>), physical activity was assessed by the International Physical Activities Questionnaire (IPAQ) and dichotomized (low versus moderate/high),<sup>41</sup> smoking was assessed by asking current smoking behavior (y/n), and alcohol use was assessed by Alcohol Use Disorders Identification (AUDIT).<sup>42</sup> The following *psychosocial factors* were included: neuroticism was assessed by the NEO-Five Factor Inventory (NEO-FFI),<sup>43</sup> childhood trauma was assessed by the Netherlands Mental Health Survey and Incidence Study (NEMESIS) Questionnaire,<sup>44</sup> partner status (y/n) was asked, loneliness was assessed by the Rasch-Type Loneliness Scale (RTL5),<sup>45</sup> social support was assessed by the Close Person Inventory and dichotomized (poor: < 2 confidants versus good: ≥ 2 confidants),<sup>46</sup> and recent life events were assessed by the Brugha Questionnaire.<sup>47</sup>

### **Statistical Analyses**

First, descriptive analyses were used to describe attrition and its determinants in the patient group (eTable 1). For both the patient group and non-depressed comparison group, attrition rates were calculated by dividing the proportion of respondents that were loss to follow-up with the total number of respondents at baseline. Subsequently, bivariate and multivariate logistic regression analyses were used to identify determinants of attrition (eTable 2).

Second, study sample characteristics were described according to the 'course of late-life



depression', in which the groups 'recurrent' and 'chronic' were combined to ensure equal group sizes for the purpose of subsequent statistical analyses (Table 1).

A correlation matrix was derived for the independent variables to rule out multicollinearity. A Pearson correlation cutoff of 0.70 was used to determine whether substantial correlation was present, and whether variables had to be left out of subsequent analysis. No correlation  $> 0.70$  was found between all the independent variables. The highest correlations observed were between BAI and neuroticism (0.52), BAI and WHODAS 2.0 (0.45). Also, the correlations between the independent variables at baseline and the dependent variable IDS at baseline, and at two-year and six-year follow-up, were retrieved. At baseline, none of the variables was correlated with IDS at  $> 0.70$ . The highest correlations observed were between IDS and WHODAS 2.0 (0.69), IDS and BAI (0.56), and IDS and neuroticism (0.54).

Bivariate multinomial regression analyses were performed to investigate the association between each prognostic factor and 'course of late-life depression', using 'full remission' as reference group (Table 2). An additional analysis was performed using 'partial remission' as reference group for the comparison with a chronic/recurrent (unfavorable) course. To overcome the study's statistical power problem, multivariate analyses were performed using Linear Mixed Models with the longitudinally measured 'symptom severity of depression' (IDS) as dependent variable (Table 3). First, group wise multivariate analyses were conducted for each of the three separate domains. Subsequently, the final multivariate model contained all prognostic factors that were associated with IDS at  $p < .05$  from the group wise multivariate analyses. The goodness of fit for all multivariate models was evaluated with the -2 Log Likelihood (-2LL) method by comparing the fitted fixed-effects models to the model with no predictors (null model). We evaluated changes in the -2LL

between the null model and each fitted fixed-effects model. Analyses were performed using IBM SPSS 22.0.

postprint

## Results (Words: 550)

### Attrition of NESDO

Figure 1 contains the flowchart of NESDO. From the 510 respondents at baseline, 299 participated in the six-year follow-up assessment with an overall attrition rate of 41.4%. The attrition rate between two- and six-year follow-up was 25.4%. The attrition rates for the patient and comparison group differed at 46.8% and 25.8%, respectively. The most important reasons for attrition in the patient group were mortality (16.4%) and mental reasons (15.1%), mainly cognitive impairment, whereas the most important reason for attrition in the non-depressed comparison group was refusal (9.1%). A total of seventy participants (13.7%) died during six-year follow-up, including sixty-two depressed patients and eight non-depressed comparisons. The relative risk of mortality among depressed patients was 2.47 time (95% CI: 1.26-4.81) higher when compared with non-depressed comparisons,  $\chi^2(1) = 8.84, p=.003$ .

Among depressed patients, attrition was the same for men and women,  $\chi^2(1) = 0.78, p=.38$  (eTable 1). In bivariate analyses (eTable 2), determinants of attrition in the patient group were higher age (OR: 1.08, 95%-CI: 1.05-1.11), less education (OR: 0.93, 95%-CI: 0.87-0.98), a higher age of onset of depression (OR: 1.01, 95%-CI: 1.00-1.02), worse cognitive functioning (OR: 0.79, 95%-CI: 0.71-0.88), and less physical activity (OR: 2.01, 95%-CI: 1.28-3.15). In multivariate analyses, age (OR: 1.06, 95%-CI: 1.03-1.09) and global cognitive functioning (OR: 0.83, 95%-CI: 0.75-0.95) remained significantly associated with attrition in the patient group.

## Prognosis of late-life depression

Among the total of 378 depressed patients at baseline, 177 (46.8%) were loss to follow-up, 60 (15.9%) had a recurrent or chronic depression, 93 (24.6%) had a partial remission and only 48 (12.7%) had a full remission at six-year follow-up. Of those with a full remission at six years, 43.8% reached this after two years.

Table 1 shows the characteristics from 201 clinically depressed patients who were able to participate in the study over the full six years according to their course type. This sample consisted of 137 (68.2%) women, and the mean age of the sample was 69.0 (SD: 6.5) years. Sixty (29.9%) depressed patients had an unfavorable course type (8.0% recurrent, 21.9% chronic), 93 (46.3%) had a partial remission, and 48 (23.9%) had a full remission. The symptom severity levels of depression (IDS) at six-month intervals according to the prognosis of depressed patients after six-year follow-up is shown in Figure 2.

## Prognostic factors

In Table 2, results from bivariate analyses demonstrate that the depression-related clinical factors: younger age of onset of depression, higher severity of depression, higher severity of anxiety, and more apathy; the health and lifestyle factors: chronic diseases, functional limitations, and chronic pain; and the psychosocial factors: neuroticism and loneliness were all associated with an unfavorable course type as compared to full remission. As compared to full remission, partial remission was only associated with chronic diseases and loneliness, and not with any of the depression-related clinical factors. As compared to partial remission, an unfavorable course type was associated with a younger age of onset of depression, higher severity of depression, a comorbid anxiety disorder, higher severity of anxiety, use of

antidepressants, functional limitations, less physical activity, less alcohol use, and neuroticism.

From multivariate longitudinal analyses (Table 3), a younger age of onset of depression, higher severity of depression, chronic pain, neuroticism, and loneliness at baseline were significantly associated with higher levels of depression over the six-year follow-up.

postprint

## **Discussion (Words: 1124)**

The most important conclusion to be drawn from this study among depressed older patients is that the long-term prognosis for this group is poor in terms of mortality and course of depression. Attrition in the patient group was almost twice as high as in the comparison group. During six-years of follow-up, nearly 47% of the depressed patients were loss to follow-up, mainly due to mortality (relative risk of 2.5 versus non-depressed comparisons) and cognitive impairment. Sixteen percent had an unfavorable course type, i.e. chronic or recurrent, 25% had a partial remission, and only 13% had a full remission. Nonetheless, almost half of those reaching full remission at six-year follow-up still had clinically relevant depression at two-year follow-up, which is an important finding and should encourage clinicians to prolong and optimize treatment in depressed older patients, even after two years.

We also demonstrated that results were biased in the direction of a more favorable prognosis if attrition was excluded as outcome, as this may lead to a selection of the more healthy and motivated patients (30% would have had an unfavorable course, 46% partial remission and 24% full remission). Furthermore, strict criteria were used to define full remission, as a result of which the proportion of patients with a full remission may be underestimated. The rationale for this decision was based on the previous finding that residual symptoms have been associated with a poor outcome,<sup>48,49</sup> indicating that the goal must be to keep the patient as symptom-free as possible.<sup>48</sup>

In a longitudinal study of 127 depressed older patients in the community, it was shown that at three years, 30% had died, 35% had a chronic or recurrent depression, 25% had another mental illness, and only 10% had maintained a full remission.<sup>5</sup> Stek et al. (2002) examined the long-term prognosis of major depression in hospitalized older patients six to

eight year after clinical treatment and found that 40% had died, while among the survivors 33% had no residual symptoms or relapses,<sup>11</sup> which approximately corresponds to our finding that among survivors 24% reached full remission. These numbers from both community and clinical studies are in line with our results and strongly indicate that depression in later life is a disabling chronic disorder with a poor outcome.

Depression is a complex multifactorial disease, implicating that multiple factors from different domains of functioning contribute to its onset and prognosis.<sup>21</sup> This study found that an unfavorable course of depression was associated with a younger age of onset of depression, a higher severity of depression, chronic pain, neuroticism, and loneliness, which is in accordance with current literature.<sup>4,26,28,50,51</sup> Furthermore, partial remission could not be distinguished from full remission using depression-related clinical factors, but was more likely associated with chronic diseases and loneliness. This finding could imply that these factors are important targets for interventions to prevent relapse, as partial remission is a strong predictor of relapse and chronicity.<sup>52</sup> Our findings do not point to single factors that may be important for the prognosis of depression, but rather point to multiple factors from different domains of functioning that all are important, with each factor having a small but significant contribution.

Recently, Brown et al. (2017) found that biological age was more important than chronological age in predicting the incidence and course of depressive symptoms over long-term follow-up.<sup>53</sup> The authors stated that their findings support the evolving biological view of late-life depression as resulting from deleterious age-associated changes.<sup>53,54</sup> Our study suggests however that a more holistic view allowing identification of non-biological factors as well, is appropriate in targeting older adults at risk for an unfavorable prognosis and thus for prevention and treatment interventions.<sup>21,50</sup>

Our study has some limitations. First, because of a lack of power, multivariate analyses were not performed on course types, making it difficult to clarify the strongest prognostic factors of an unfavorable course type. On the other hand, we did perform multivariate analyses using mixed models with the IDS as assessed every six months, which allowed a more accurate assessment of prognostic factors. Second, there might be a great chance of a Type I error due to multiple statistical comparisons. However, on a theoretical basis, we included multiple factors from biopsychosocial domains of functioning that have been previously associated with a poor outcome of late-life depression in studies to date, thereby minimizing the risk of Type I error (or chance). Also, most of the variables that remained statistically significant ( $p < 0.05$ ) in the final multivariate model, had a stronger association with the outcome in the preceding groupwise models at  $p \leq 0.01$  (except for 'age of onset'). Furthermore, predictors that were associated with a poor outcome from multinomial regression analyses, are more or less the same predictors that were associated with a poor outcome from mixed model analyses, which should affirm the validity of our findings. Moreover, the factors uncovered in this study are in line with previous research, from which we think that our results are solid and accurate. Third, although the strength of NESDO is that the results generalize to clinical practice, they are not generalizable to the community. Moreover, in the Netherlands general practitioners provide primary care for depression. Depressed patients who do not recover are subsequently referred to specialist mental health care. This situation may have induced some selection bias in our sample, with relatively many patients with a treatment-resistant depression. Finally, by using depression diagnosis at two measurement points over six years, information was lacking on short-term relapses and recurrences in between these measurements. Since recurrence and chronicity are both unfavorable outcomes, this limitation was tackled by combining both groups. For



future research, a latent class analysis on the IDS data would provide more detailed information about detailed trajectories of depression.

Despite of the limitations, the study has numerous strengths. The prognosis of late-life depression was captured based on the depression diagnosis according to DSM-criteria in combination with the IDS at separate measurement points over six years, which increases the external validity and usability for clinicians. Furthermore, we did not only examine the course, but also attrition among patients with late-life depression, which made it additionally clear that the long-term prognosis of late-life depression is poor.

The clinical implication of this study may be that a multidimensional approach targeting the uncovered factors is valuable in improving the prognosis of late-life depression. Depressed patients with a partial remission might benefit further from interventions targeting chronic diseases and loneliness to obtain full recovery. At the same time, the risk of a poor outcome, such as chronicity, cognitive impairment, or death may be inevitable in depressed patients when their depression is more severe, started at a younger age, and if health and psychosocial problems also exist. Careful long-term monitoring of depression among older adults may be key in optimizing maintenance treatment strategies.

## **Acknowledgements**

**Author Contributions:** H.W. Jeurig, MD, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Study concept and design:* Comijs, Oude Voshaar, Van der Mast, Naarding, Stek, Beekman

*Acquisition, analysis, or interpretation of data:* All authors

*Drafting of the manuscript:* Jeurig

*Critical revision of the manuscript for important intellectual content:* All authors

*Administrative, technical or material support:* Comijs, Beekman

*Study supervision:* Comijs, Stek, Huisman, Beekman

**Funding/Support:** The infrastructure for the NESDO study (<http://nesdo.amstad.nl>) is funded through the Fonds NutsOhra (project 0701-065), Stichting tot Steun VCVGZ, NARSAD The Brain and Behaviour Research Fund (grant ID 41080), and the participating universities and mental health care organizations (VU University Medical Center, Leiden University Medical Center, University Medical Center Groningen, UMC St. Radboud, and GGZ InGeest, GG Net, GGZ Nijmegen and Parnassia).

**Role of the Funder/Sponsor:** The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

**Conflict of Interest Disclosures:** None.

**Additional contributions:** We thank participants and interviewers of the NESDO study.

## References

1. Power C, Greene E, Lawlor BA. Depression in Late Life: Etiology, Presentation, and Management. *Ment Heal Illn Elder*. 2017;1-31. doi:10.1007/978-981-10-0370-7\_10-1.
2. Haigh EAP, Bogucki OE, Sigmon ST, Blazer DG. Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions. *Am J Geriatr Psychiatry*. June 2017. doi:10.1016/j.jagp.2017.06.011.
3. Singh-Manoux A, Dugravot A, Fournier A, et al. Trajectories of Depressive Symptoms Before Diagnosis of Dementia. *JAMA Psychiatry*. 2017;74(7):712. doi:10.1001/jamapsychiatry.2017.0660.
4. Blazer DG. Depression in late life: Review and commentary. *J Gerontol*. 2003;58(3):249-265. doi:10.1093/gerona/58.3.M249.
5. Denihan A, Kirby M, Bruce I, Cunningham C, Coakley D, Lawlor BA. Three-year prognosis of depression in the community-dwelling elderly. *Br J Psychiatry*. 2000;176(MAY):453-457. doi:10.1192/bjp.176.5.453.
6. Beekman ATF, Geerlings S, Deeg D, et al. The Natural History of Late-Life Depression. *Arch Gen Psychiatry*. 2002;59(July 2002):605-611. doi:10.1001/archpsyc.59.7.605.
7. Henderson AS, Korten AE, Jacomb PA, et al. The course of depression in the elderly: a longitudinal community-based study in Australia. *Psychol Med*. 1997;27(1):119-129. doi:10.1017/S0033291796004199.
8. Sharma VK, Copeland JR, Dewey ME, Lowe D, Davidson I. Outcome of the depressed elderly living in the community in Liverpool: a 5-year follow-up. *Psychol Med*. 1998;28(6):1329-1337. <http://www.ncbi.nlm.nih.gov/pubmed/9854274>.
9. Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. A 25-year longitudinal, comparison study of the outcome of depression. *Psychol Med*. 2001;31(8):1347-1359. doi:10.1017/S0033291701004743.
10. Lyness JM, Caine ED, King D a, Conwell Y, Duberstein PR, Cox C. Depressive disorders and symptoms in older primary care patients: one-year outcomes. *Am J Geriatr Psychiatry*. 2002;10(3):275-282. <http://www.ncbi.nlm.nih.gov/pubmed/11994214>.
11. Stek ML, Van Exel E, Van Tilburg W, Westendorp RGJ, Beekman ATF. The prognosis of depression in old age: Outcome six to eight years after clinical treatment. *Aging Ment Heal*. 2002;6(3):282-285. doi:10.1080/13607860220142413.
12. Hybels CF, Pieper CF, Blazer DG, Steffens DC. Heterogeneity in the three-year course

- of major depression among older adults. *Int J Geriatr Psychiatry*. 2016;31(7):775-782. doi:10.1002/gps.4391.
13. Comijs HC, Nieuwesteeg J, Kok R, et al. The two-year course of late-life depression; results from the Netherlands study of depression in older persons. *BMC Psychiatry*. 2015;15(1):20. doi:10.1186/s12888-015-0401-5.
  14. Katon WJ, Fan M-Y, Lin EHB, Unützer J. Depressive symptom deterioration in a large primary care-based elderly cohort. *Am J Geriatr psychiatry*. 2006;14(3):246-254. doi:10.1097/01.JGP.0000196630.57751.44.
  15. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: A systematic review of comparative studies. *Am J Psychiatry*. 2005;162(9):1588-1601. doi:10.1176/appi.ajp.162.9.1588.
  16. Kok RM, Reynolds CF. Management of Depression in Older Adults. *JAMA*. 2017;317(20):2114. doi:10.1001/jama.2017.5706.
  17. Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam B, Bruce ML. Clinical Presentation of the “Depression–Executive Dysfunction Syndrome” of Late Life. *Am J Geriatr Psychiatry*. 2002;10(1):98-106. doi:10.1097/00019442-200201000-00012.
  18. Groeneweg-Koolhoven I, Ploeg M, Comijs HC, et al. Apathy in early and late-life depression. *J Affect Disord*. 2017;223:76-81. doi:10.1016/j.jad.2017.07.022.
  19. Yuen GS, Bhutani S, Lucas BJ, et al. Apathy in late-life depression: Common, persistent, and disabling. *Am J Geriatr Psychiatry*. 2015;23(5):488-494. doi:10.1016/j.jagp.2014.06.005.
  20. Rhebergen D, Lamers F, Spijker J, de Graaf R, Beekman ATF, Penninx BWJH. Course trajectories of unipolar depressive disorders identified by latent class growth analysis. *Psychol Med*. 2012;42(7):1383-1396. doi:10.1017/S0033291711002509.
  21. Blazer DG, Hybels CF. Origins of depression in later life. *Psychol Med*. 2005;35(9):1241. doi:10.1017/S0033291705004411.
  22. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: Controlled study. *Br J Psychiatry*. 2007;190(APR.):344-349. doi:10.1192/bjp.bp.106.027169.
  23. Kennedy GJ, Kelman HR, Thomas C. Persistence and remission of depressive symptoms in late life. *Am J Psychiatry*. 1991;148(2):174-178. doi:10.1176/ajp.148.2.174.

24. Bruce ML. Depression and disability in late life: directions for future research. *Am J Geriatr Psychiatry*. 2001;9(2):102-112. doi:10.1097/00019442-200105000-00003.
25. Karp JF, Weiner D, Seligman K, et al. Body Pain and Treatment Response in Late-Life Depression. *Am J Geriatr Psychiatry*. 2005;13(3):188-194. doi:10.1097/00019442-200503000-00003.
26. Holvast F, Burger H, De Waal MMW, Van Marwijk HWJ, Comijs HC, Verhaak PFM. Loneliness is associated with poor prognosis in late-life depression: Longitudinal analysis of the Netherlands study of depression in older persons. *J Affect Disord*. 2015;185:1-7. doi:10.1016/j.jad.2015.06.036.
27. Wielaard I, Comijs HC, Stek ML, Rhebergen D. Childhood Abuse and the Two-Year Course of Late-Life Depression. *Am J Geriatr Psychiatry*. 2017;25(6):633-643. doi:10.1016/j.jagp.2017.01.014.
28. Manning KJ, Chan G, Steffens DC. Neuroticism Traits Selectively Impact Long Term Illness Course and Cognitive Decline in Late-Life Depression. *Am J Geriatr Psychiatry*. 2017;25(3):220-229. doi:10.1016/j.jagp.2016.10.006.
29. Comijs H, Van Marwijk H, Van der Mast R, et al. The Netherlands study of depression in older persons (NESDO); a prospective cohort study. *BMC Res Notes*. 2011;4(1):524. doi:10.1186/1756-0500-4-524.
30. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. *Am Psychiatr Assoc*. 2000. doi:10.1176/appi.books.9780890423349.
31. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. *Psychol Med*. 1996;26(3):477. doi:10.1017/S0033291700035558.
32. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psych. *Psychol Med*. 2004;34(1):S0033291703001107. doi:10.1017/S0033291703001107.
33. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. *J Consult Clin Psychol*. 1988;56(6):893-897. doi:10.1037/0022-006X.56.6.893.

34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6.
35. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. *J Neuropsychiatry Clin Neurosci*. 1992;4(2):134-139. doi:10.1176/jnp.4.2.134.
36. Levine DW, Kaplan RM, Kripke DF, Bowen DJ, Naughton MJ, Shumaker SA. Factor structure and measurement invariance of the Women's Health Initiative Insomnia Rating Scale. *Psychol Assess*. 2003;15(2):123-136. doi:10.1037/1040-3590.15.2.123.
37. Kriegsman DMW, Penninx BWJH, van Eijk JTM, Boeke AJJP, Deeg DJH. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. *J Clin Epidemiol*. 1996;49(12):1407-1417. doi:10.1016/S0895-4356(96)00274-0.
38. Chwastiak LA, Von Korff M. Disability in depression and back pain: Evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary care setting. *J Clin Epidemiol*. 2003;56(6):507-514. doi:10.1016/S0895-4356(03)00051-9.
39. Marijnissen RM, Smits JEMP, Schoevers RA, et al. Association between metabolic syndrome and depressive symptom profiles—Sex-specific? *J Affect Disord*. 2013;151(3):1138-1142. doi:10.1016/j.jad.2013.07.029.
40. Von Korff M, Miglioretti DL. A prognostic approach to defining chronic pain. *Pain*. 2005;117(3):304-313. doi:10.1016/j.pain.2005.06.017.
41. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-Country reliability and validity. *Med Sci Sports Exerc*. 2003;35(8):1381-1395. doi:10.1249/01.MSS.0000078924.61453.FB.
42. Babor TF, Kranzler HR, Lauerma RJ. Early detection of harmful alcohol consumption: Comparison of clinical, laboratory, and self-report screening procedures. *Addict Behav*. 1989;14(2):139-157. doi:10.1016/0306-4603(89)90043-9.
43. Costa Jr. PT, McCrae RR. Domains and Facets: Hierarchical Personality Assessment Using the Revised NEO Personality Inventory. *J Pers Assess*. 1995;64(1):21-50. doi:10.1207/s15327752jpa6401\_2.
44. De Graaf R, Bijl R V., Ten Have M, Beekman ATF, Vollebergh WAM. Pathways to

- comorbidity: The transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. *J Affect Disord*. 2004;82(3):461-467. doi:10.1016/j.jad.2004.03.001.
45. de Jong-Gierveld J, Kamphuls F. The Development of a Rasch-Type Loneliness Scale. *Appl Psychol Meas*. 1985;9(3):289-299. doi:10.1177/014662168500900307.
  46. Stansfeld S, Marmot M. Deriving a survey measure of social support: The reliability and validity of the close persons questionnaire. *Soc Sci Med*. 1992;35(8):1027-1035. doi:10.1016/0277-9536(92)90242-I.
  47. Brugha T, Bebbington P, Tennant C, Hurry J. The List of Threatening Experiences: a subset of 12 life event categories with considerable long-term contextual threat. *Psychol Med*. 1985;15(1):189-194. doi:10.1017/S003329170002105X.
  48. Judd LL. Dimensional paradigm of the long-term course of unipolar major depressive disorder. *Depress Anxiety*. 2012;29(3):167-171. doi:10.1002/da.21934.
  49. Meeks TW, Vahia I V., Lavretsky H, Kulkarni G, Jeste D V. A tune in “a minor” can “b major”: A review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. *J Affect Disord*. 2011;129(1-3):126-142. doi:10.1016/j.jad.2010.09.015.
  50. Fiske A, Wetherell JL, Gatz M. Depression in Older Adults. *Annu Rev Clin Psychol*. 2009;5(1):363-389. doi:10.1146/annurev.clinpsy.032408.153621.
  51. Tunvirachaisakul C, Gould RL, Coulson MC, et al. Predictors of treatment outcome in depression in later life: A systematic review and meta-analysis. *J Affect Disord*. 2017;227:164-182. doi:10.1016/j.jad.2017.10.008.
  52. Steffens DC, McQuoid DR, Krishnan KRR. Partial response as a predictor of outcome in geriatric depression. *Am J Geriatr Psychiatry*. 2003;11(3):340-348. <http://www.ncbi.nlm.nih.gov/pubmed/12724113>.
  53. Brown PJ, Wall MM, Chen C, et al. Biological Age, Not Chronological Age, is Associated with Late Life Depression. *Journals Gerontol Ser A*. August 2017. doi:10.1093/GERONA/GLX162.
  54. Rutherford BR, Taylor WD, Brown PJ, Sneed JR, Roose SP. Biological aging and the future of geriatric psychiatry. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2016;72(3):343-352. doi:10.1093/gerona/glw241.

1 **Figure legends**

2 **Figure 1:** Flowchart of NESDO and long-term prognosis of late-life depression.

3

4 **Figure 2.** Symptom severity levels of depression (IDS) at six-month intervals according to the  
5 prognosis of depressed patients after six-year follow-up.

postprint



postprint

**Table 1. Characteristics of N=201 depressed patients at baseline and according to their course type of late-life depression at follow-up.**

	Baseline	Six-year follow-up, course types		
	Total N=201	Full remission N=48	Partial remission N=93	Recurrent or Chronic N=60
<b>Prognostic factors</b>				
<b>Demographics</b>				
Women, N (%)	137 (68.2)	28 (58.3)	66 (71.0)	43 (71.7)
Age, years, mean (SD)	69.0 (6.5)	68.4 (5.9)	69.5 (6.8)	68.5 (6.5)
Education, years, mean (SD)	10.9 (3.5)	10.8 (3.1)	10.8 (3.4)	11.0 (4.0)
<b>Depression-related clinical factors</b>				
Previous episode depression, yes, N (%)	175 (90.2)	41 (87.2)	80 (90.9)	54 (91.5)
Age of onset of depression, mean (SD)	46.3 (19.7)	48.4 (18.3)	49.1 (18.5)	40.5 (21.4)
Severity depressive symptoms, mean (SD)	29.7 (12.5)	26.0 (13.6)	28.5 (10.2)	34.5 (13.6)
Comorbid anxiety diagnosis, yes, N (%)	79 (39.3)	17 (35.4)	30 (32.3)	32 (53.3)
Severity anxiety symptoms, mean (SD)	16.8 (10.7)	14.3 (10.6)	15.6 (9.2)	20.6 (12.1)
Global Cognitive Functioning, mean (SD)	28.1 (1.6)	28.1 (1.5)	28.3 (1.4)	27.8 (2.0)
Apathy, mean (SD)	16.8 (5.3)	15.3 (5.2)	17.1 (5.4)	17.5 (5.2)
Sleep problems, mean (SD)	10.9 (5.2)	11.0 (5.7)	10.6 (5.1)	11.3 (5.1)
Use of antidepressants, yes, N (%)	145 (72.9)	37 (78.7)	58 (63.0)	50 (83.3)
Frequent use of benzodiazepines, yes, N (%)	73 (36.3)	20 (41.7)	29 (31.2)	24 (36.3)
<b>Health and lifestyle factors</b>				
Chronic diseases, mean (SD)	2.1 (1.5)	1.5 (1.0)	2.1 (1.5)	2.5 (1.8)
Functional Limitations, mean (SD)	25.0 (12.3)	23.5 (11.9)	23.4 (11.2)	28.6 (13.7)
Metabolic syndrome, original ATP III criteria, yes, N (%)	61 (30.3)	11 (22.9)	32 (34.4)	18 (30.0)
Chronic Pain, yes, N (%)	111 (55.5)	23 (47.9)	48 (51.6)	40 (67.8)
Body-Mass-Index, mean (SD)	26.1 (4.3)	25.1 (3.7)	26.3 (4.2)	26.6 (4.8)
Physical activity, low, N (%)	47 (24.1)	13 (28.3)	15 (16.7)	19 (32.2)
Smoking, yes, N (%)	47 (23.4)	10 (20.8)	24 (25.8)	13 (21.7)
Alcohol, AUDIT, median (IQR)	2 (4)	2 (4)	3 (5)	0 (3)
<b>Psychological and social factors</b>				
Neuroticism, mean (SD)	39.1 (6.2)	37.1 (5.9)	38.5 (4.9)	41.7 (7.4)
Childhood Trauma Index, mean (SD)	1.0 (1.2)	0.9 (1.1)	1.0 (1.1)	1.2 (1.3)
Partner, no, N (%)	95 (47.3)	20 (41.7)	48 (51.6)	27 (45.0)

Loneliness, mean (SD)	6.6 (3.5)	4.8 (3.3)	7.0 (3.4)	7.5 (3.3)
Social support, poor, N (%)	96 (48.0)	23 (48.9)	44 (47.3)	29 (48.3)
Recent life events, mean (SD)	1.8 (1.3)	1.6 (1.3)	1.9 (1.4)	1.8 (1.3)

7 SD = standard deviation; IQR = interquartile range; AUDIT = Alcohol Use Disorders Identification Test.

postprint

**Table 2. Prognostic factors associated with long-term course types of late-life depression from bivariate analyses using multinomial logistic regression.**

Prognostic factors	Partial remission (ref: full remission)				Recurrent or Chronic (ref: full remission)				Recurrent or Chronic (ref: partial remission)			
	OR	95% CI	Wald $\chi^2$	p-value	OR	95% CI	Wald $\chi^2$	p-value	OR	95% CI	Wald $\chi^2$	p-value
<b>Demographics</b>												
Women	1.75	(0.84-3.62)	2.25	.13	1.81	(0.81-4.03)	2.09	.15	1.04	(0.51-2.12)	0.01	.93
Age	1.03	(0.97-1.08)	0.89	.35	1.00	(0.94-1.06)	0.01	.95	0.98	(0.93-1.03)	0.88	.35
Education	1.00	(0.90-1.11)	0.00	.99	1.02	(0.92-1.14)	0.15	.70	1.02	(0.93-1.12)	0.22	.64
<b>Depression-related clinical factors</b>												
Previous episode depression, yes	1.46	(0.48-4.50)	0.44	.51	1.58	(0.45-5.54)	0.51	.47	1.08	(0.34-3.48)	0.02	.90
Age of onset of depression	1.00	(0.98-1.02)	0.04	.84	0.98	(0.96-1.00)	4.11	.043	0.98	(0.96-0.99)	6.59	.010
Severity depressive symptoms	1.02	(0.99-1.05)	1.36	.24	1.06	(1.02-1.10)	11.27	.001	1.04	(1.01-1.07)	8.07	.005
Comorbid anxiety diagnosis, yes	0.87	(0.42-1.81)	0.14	.71	2.08	(0.96-4.54)	3.41	.065	2.40	(1.23-4.68)	6.60	.010
Severity anxiety symptoms	1.01	(0.98-1.05)	0.46	.50	1.06	(1.02-1.10)	7.68	.006	1.04	(1.01-1.08)	6.99	.008
Global Cognitive Functioning	1.08	(0.87-1.34)	0.45	.50	0.90	(0.72-1.13)	0.83	.36	0.84	(0.69-1.02)	3.16	.076
Apathy	1.07	(1.00-1.14)	3.36	.067	1.08	(1.00-1.17)	4.24	.040	1.01	(0.95-1.08)	0.20	.66
Sleep problems	0.99	(0.92-1.06)	0.17	.68	1.01	(0.94-1.09)	0.12	.73	1.03	(0.97-1.10)	0.73	.39
Use of antidepressants, yes	0.46	(0.20-1.04)	3.45	.063	1.35	(0.51-3.58)	0.37	.55	2.93	(1.32-6.52)	6.94	.008
Use of benzodiazepines, yes	0.63	(0.31-1.31)	1.53	.22	0.93	(0.43-2.02)	0.03	.86	1.47	(0.75-2.90)	1.25	.26
<b>Health and lifestyle factors</b>												
Chronic diseases	1.42	(1.08-1.87)	6.15	.013	1.65	(1.23-2.21)	10.99	.001	1.16	(0.94-1.43)	1.95	.16
Functional Limitations	1.00	(0.97-1.03)	0.00	.95	1.04	(1.00-1.07)	4.34	.037	1.04	(1.01-1.07)	6.29	.012
Metabolic syndrome, yes	1.77	(0.80-3.92)	1.95	.16	1.44	(0.60-3.44)	0.68	.41	0.82	(0.41-1.64)	0.32	.57
Chronic Pain, yes	1.16	(0.58-2.33)	0.17	.68	2.29	(1.04-5.03)	4.25	.039	1.97	(0.99-3.90)	3.83	.050
Body-Mass-Index	1.08	(0.98-1.18)	2.57	.11	1.10	(1.00-1.21)	3.50	.061	1.02	(0.95-1.10)	0.23	.63
Physical activity, low	0.51	(0.22-1.19)	2.45	.12	1.21	(0.52-2.80)	0.19	.66	2.38	(1.09-5.17)	4.75	.029
Smoking, yes	1.32	(0.57-3.05)	0.43	.51	1.05	(0.42-2.66)	0.01	.92	0.80	(0.37-1.72)	0.34	.56
Alcohol use	1.05	(0.95-1.16)	0.78	.38	0.89	(0.77-1.03)	2.43	.12	0.85	(0.75-0.97)	5.90	.015
<b>Psychological and social factors</b>												
Neuroticism	1.04	(0.98-1.10)	1.53	.22	1.14	(1.06-1.22)	12.90	<.001	1.09	(1.03-1.16)	8.98	.003
Childhood Trauma Index	1.11	(0.81-1.52)	0.39	.53	1.26	(0.90-1.76)	1.83	.18	1.14	(0.87-1.50)	0.88	.35
Partner, no	0.67	(0.33-1.35)	1.25	.26	0.87	(0.41-1.88)	0.12	.73	1.30	(0.68-2.50)	0.64	.43
Loneliness	1.20	(1.08-1.34)	10.78	.001	1.26	(1.11-1.42)	13.58	<.001	1.05	(0.94-1.16)	0.75	.39
Social support, poor	0.94	(0.46-1.89)	0.03	.86	0.98	(0.46-2.10)	0.00	.95	1.04	(0.54-2.00)	0.02	.90
Recent life events	1.24	(0.95-1.63)	2.45	.12	1.17	(0.88-1.57)	1.13	.29	0.95	(0.74-1.20)	0.21	.65

8 OR = odds ratio; CI = confidence interval; degrees of freedom for Wald  $\chi^2$  statistic = 1.

**Table 3. Prognostic factors associated with higher symptom levels of depression during six years from bivariate and multivariate linear mixed models analyses.**

Prognostic factors	Bivariate models			Multivariate models, group wise			Multivariate model, final		
	$\beta$ (SE)	p-value	df.	$\beta$ (SE)	p-value	df.	$\beta$ (SE)	p-value	df.
<b>Demographics</b>									
Women	2.24 (1.60)	.16	198						
Age	-0.03 (0.12)	.79	199						
Education	0.04 (0.22)	.87	199						
<b>a) Depression-related clinical factors</b>				<b>group wise model a</b>					
Previous episode depression, yes	7.70 (2.52)	.003	191	-0.18 (2.19)	.93	165			
Age of onset of depression	-0.16 (0.04)	<.001	193	-0.08 (0.03)	.017	165	-0.06 (0.03)	.040	166
Severity depressive symptoms	0.55 (0.05)	<.001	198	0.40 (0.06)	<.001	167	0.32 (0.07)	<.001	168
Comorbid anxiety diagnosis, yes	3.73 (1.51)	.014	198	0.88 (1.23)	.48	165			
Severity anxiety symptoms	0.51 (0.06)	<.001	189	0.22 (0.07)	.002	168	0.11 (0.07)	.11	170
Global Cognitive Functioning	-0.57 (0.46)	.22	201						
Apathy	0.69 (0.14)	<.001	188	0.30 (0.12)	.011	166	0.15 (0.12)	.20	166
Sleep problems	0.57 (0.14)	<.001	190	-0.09 (0.13)	.48	165			
Use of antidepressants, yes	-0.52 (1.70)	.76	196						
Use of benzodiazepines, yes	-0.25 (1.56)	.87	198						
<b>b) Health and lifestyle factors</b>				<b>group wise model b</b>					
Chronic diseases	2.70 (0.45)	<.001	198	1.43 (0.43)	.001	187	0.68 (0.39)	.084	165
Functional Limitations	0.41 (0.05)	<.001	192	0.25 (0.06)	<.001	187	-0.05 (0.06)	.46	168
Metabolic syndrome, yes	3.92 (1.61)	.015	199	-0.68 (1.52)	.66	188			
Chronic Pain, yes	7.80 (1.39)	<.001	198	4.22 (1.32)	.002	188	2.60 (1.21)	.033	167
Body-Mass-Index	0.81 (0.17)	<.001	201	0.46 (0.17)	.009	189	0.23 (0.14)	.12	167
Physical activity, low	-1.41 (1.79)	.43	193						
Smoking, yes	0.92 (1.77)	.60	198						
Alcohol use	-0.47 (0.21)	.025	196	-0.14 (0.18)	.43	186			
<b>c) Psychological and social factors</b>				<b>group wise model c</b>					
Neuroticism	0.89 (0.11)	<.001	188	0.73 (0.11)	<.001	185	0.24 (0.12)	.043	167
Childhood Trauma Index	1.56 (0.64)	.015	198	0.81 (0.55)	.15	184			
Partner, no	1.15 (1.50)	.44	198						
Loneliness	1.18 (0.21)	<.001	188	0.70 (0.20)	.001	185	0.39 (0.18)	.036	166
Social support, poor	-0.19 (1.50)	.90	197						
Recent life events	0.53 (0.56)	.35	198						

9  $\beta$  = regression coefficient; SE = standard error; df. = degrees of freedom, rounded to ones. p-values for the regression coefficients were generated with t-tests.

10 Multivariate group wise analyses contains factors that were associated with  $p < 0.05$  in bivariate analyses, for each domain (a-c). The final multivariate model contains all  
11 factors that were associated with  $p < 0.05$  in the multivariate group wise analyses (a-c). Goodness of fit: model a ( $\chi^2(7) = 2370.073$ ,  $p < .001$ ), model b ( $\chi^2(6) = 607.702$ ,  
12  $p < .001$ ), model c ( $\chi^2(3) = 956.429$ ,  $p < .001$ ), final model ( $\chi^2(10) = 2042.444$ ,  $p < .001$ ).

postprint